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Abstract
Background: Imepitoin is a novel antiepileptic drug for the treatment of canine idiopathic epilepsy. The present
study was conducted to demonstrate superior antiepileptic activity of a high dose of 30 mg/kg BID over a low dose
of 1 mg/kg BID of imepitoin during 12 weeks of treatment under double blind conditions in a field population of dogs
with previously untreated epilepsy. In a consecutive 12 weeks open label follow up (phase 2), all animals received
30 mg/kg BID, to evaluate the persistence of the antiepileptic activity, and to evaluate the effect of a dose step up to
30 mg/kg in the former low-dose animals.
Results: A treatment with 30 mg/kg BID resulted in a significantly greater reduction in monthly seizure frequency
relative to baseline data as compared to the 1 mg/kg dose. Both generalized and partial seizures but not cluster
seizures were significantly less frequent in the high dose group. The antiepileptic activity was maintained during
study phase 2 in the high dose group. An increase to 30 mg/kg BID in the low- dose animals resulted in a significant
reduction in generalized and partial seizures, but not cluster seizures. At the end of study phase 2, 32.1 and 46.8 % of
dogs of the former high and former low-dose groups respectively, remained free of generalized tonic-clonic seizures.
Imepitoin was well tolerated. The frequency of dogs with any adverse drug reactions was higher in the 30 mg/kg BID
dose (59 % vs. 41 %, p = 0.041), and the main target organ was the central nervous system (CNS). The occurrence of
CNS related adverse reactions was transient and findings were mostly restricted to the first weeks of treatment. No
hepatic enzyme increase and no other organ toxicity were observed.
Conclusion: The administration of imepitoin twice daily at a dose of 30 mg/kg results in significant and persistent
antiepileptic effects in patients with newly diagnosed epilepsy and generalized tonic-clonic seizures, as observed
over a study period of up to 6 months. Imepitoin was well tolerated. Most CNS related adverse drug reactions
were transient. Both the antiepileptic activity and the safety profile make the drug suitable for long-term clinical use.
Keywords: Idiopathic epilepsy, Antiepileptic, Anticonvulsant, Tonic-clonic seizures, Clinical field trial
* Correspondence: chris.rundfeldt@t-online.de
1Drug-Consulting Network, 01445 Coswig, Germany
4Department of Pharmacology, Toxicology and Pharmacy, University of
Veterinary Medicine Hannover, 30559 Hannover, Germany
Full list of author information is available at the end of the article
© 2015 Rundfeldt et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rundfeldt et al. BMC Veterinary Research  (2015) 11:228 
DOI 10.1186/s12917-015-0548-9
Background
Recurrent seizures are a common neurological problem
in veterinary medicine. Seizures may occur as the result
of an acquired brain disorder (symptomatic epilepsy), or
for unknown reasons (cryptogenic epilepsy), or be due
to genetic causes, in which case it is referred to as idio-
pathic epilepsy [1]. The prevalence of canine epilepsy
was estimated to be 0.5-5 % of all dogs in the general
population or a non-referral based population [2–4], and
idiopathic epilepsy has been estimated to represent
about 60 -70 % of all cases of epilepsy in dogs [5]. In a
recent study, the prevalence was found to be 0.62 % in a
large UK population with an increased prevalence in
Border terriers and German shepherds and reduced
prevalence in West Highland white terriers [6], but idio-
pathic epilepsy can be found in a wide range of breeds
[7, 8].
The current treatment of idiopathic epilepsy is unsatis-
factory [9]. If treatment is initiated, only 15 % of cases
become seizure free and up to 30 % of canine patients
do not experience significant seizure frequency reduc-
tion with the most commonly used antiepileptic drugs
(AEDs), phenobarbital and potassium bromide [9–11].
Many of these patients are euthanized because of the se-
verity of seizures or because of severe side effects from
AEDs [12, 13]. This treatment outcome may be related
to the limited availability of treatment options for canine
epilepsy [11]. In fact, many AEDs, which have been
developed for humans are not suitable for treatment in
dogs due to inadequate pharmacokinetics or potential
for serious adverse effects, neither of which is acceptable
[14–16].
Imepitoin (AWD 131–138 or ELB 138; 1-(4-chlorophenyl)-
4-morpholino-imidazolin-2-one) is a new AED approved in
the European Union for the treatment of canine idiopathic
epilepsy. It was initially developed for the treatment of
anxiety and epilepsy in man due to both its pronounced
antiseizure activity in a large variety of rodent models of
epileptic seizures and its anxiolytic activity in predictive
rat models, combined with a high tolerability [17]. Due to
inter-individual pharmacokinetic variability in man, which
was related to smoking-related induction of metabolic en-
zymes, the human development was terminated despite
excellent tolerability [17, 18]. Based on promising findings
with imepitoin in a preclinical seizure model in dogs [19],
it was decided to develop this drug for the treatment of
canine epilepsy. Initial pilot data had indicated that
imepitoin was well tolerated in dogs and that antiepi-
leptic effects were observed both in dogs with newly
diagnosed epilepsy as monotherapy and in drug-
resistant dogs as add-on treatment to phenobarbital
[20]. The aim of this study was to confirm the antiepi-
leptic activity and safety of imepitoin in dogs with idio-
pathic epilepsy in a well-controlled randomized double
blind clinical field study. In contrast to a recently
published randomized controlled parallel group study,
in which imepitoin was compared with phenobarbital
[21], the present study used a low-dose comparator
design.
Methods
Evaluation of clinical efficacy and safety under field
conditions
The study was conducted in 2003 and 2004 as a multi-
center, randomized, double blind, controlled parallel
group clinical field trial with client-owned animals in
compliance with Good Clinical Practice (GCP), aimed at
demonstrating superiority of imepitoin 30 mg/kg BID
over a low-dose of 1 mg/kg imepitoin administered BID
for 12 weeks. The choice of the two doses was based on
previous studies in dogs to represent a high but well toler-
ated dose and the lowest dose with potential antiepileptic
activity [17, 19, 20]. This first study phase was followed by
12 weeks open label treatment with 30 mg/kg BID
imepitoin (phase 2). Ethical approval was obtained
from the ethical board at Hannover Regional Council
(Bezirksregierung Hannover), file number 509.6-42502-
03A186 for part one and 509.6-42502-03A187 for part
two of the study, and from all competent local authorities
at each participating study center.
Study design
About 120 dogs with diagnosis of epilepsy with general-
ized tonic-clonic seizures were planned to be included at
a 1:1 randomization in two treatment arms. The sample
size was based on the results of our previous pilot study
[19, 20]. A sample size of at least 54 animals per group
was calculated to be able to detect a difference of at least
one seizure per 28 days with a standard deviation of 1.83
seizures per 28 days, significance level 0.05 and power
80 % (t-test). Aiming at including patients with idiopathic
epilepsy, the study excluded animals with either reactive
seizures or progressive intracranial disease. However, mag-
netic resonance imaging (MRI) and cerebrospinal fluid
(CSF) examination was not made mandatory for the diag-
nosis, making it possible that animals with other than
idiopathic epilepsy were also included. The diagnosis of
epilepsy was based on a clinical and neurological exam-
ination as described by Vandevelde et al., 2001 [22], ex-
cluding patients with clinically manifest or suspected
non-idiopathic cause. For inclusion, at least one of the
following criteria had to be fulfilled, as determined by
retrospective baseline evaluation: two to ten general-
ized tonic-clonic seizures within three months before
randomization, one cluster of tonic-clonic seizures
within seven days before randomization, or one convulsive
status epilepticus within seven days before randomization.
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Dogs were specifically excluded for enrolment if their
case history included any of the following: any treatment
with antiepileptics including phenobarbital, primidone,
or benzodiazepines for longer than four days for treatment
of seizures within three months before randomization,
intracranial disease as causes of seizures (e.g., neoplastic,
degenerative or inflammation-related), or more than ten
generalized tonic-clonic seizures within three months
before randomization. Pregnant or lactating bitches were
not included, as were dogs with a history or clinical symp-
toms of renal, cardiac, gastro-intestinal or other disorders
if the condition in the opinion of the investigator would
have exposed the dog to an unacceptable risk or compro-
mised the evaluation of the study results. In addition, the
owners had to be willing and capable to comply by written
consent with the study procedures. The use of any other
AED (e.g. phenobarbital, primidone, benzodiazepines and
bromides) was prohibited during the study. Any other
concomitant treatment or change in concomitant treat-
ment, was to be recorded.
After screening, animals were randomized to one of
two treatment arms under double blind conditions. In
the high-dose arm, dogs received a dose of 30 mg/kg
imepitoin twice daily, while in the low-dose arm the
dogs received a dose of 1 mg/kg twice daily. In order to
administer the required dose and to ensure blinding, a
number of tablets containing imepitoin or placebo and
one capsule were to be administered. The high-dose ani-
mals received tablets of 100 mg or 400 mg strength, plus
one capsule containing granulated tablet material to
achieve the exact dose of 30 mg/kg imepitoin. The low-
dose animals received a respective number of placebo
tablets matching in size and appearance to the 100 and
400 mg imepitoin tablets, plus one capsule containing
1 mg/kg imepitoin as granulated tablet material. Both,
tablets (verum or placebo) and capsules were dispensed
at a local pharmacy, where capsules were custom filled
according to the body weight of the individual dog. To
ensure randomization, the pharmacist received a pre-
scription from the local study center with the body
weight and the randomization number of the patient.
Based on a pre-defined randomization list, he assigned
the treatment group, prepared the medication, and dis-
pensed it to the patient owner. On each scheduled visit a
new prescription was filled, allowing adjustment of the
dose to the actual body weight. This procedure ensured
that the respective treatment center and the patient
owners remained blinded to the treatment. The treat-
ment duration during phase 1 was scheduled to be
84 days. Visits after inclusion were scheduled after 4, 8,
and finally after 12 weeks, +/− 7 days.
Prior to enrolment, the investigators, in collaboration
with the owners, documented retrospectively the number
and type of seizures, cluster seizures, and convulsive status
epilepticus within three months before randomization, to
evaluate the seizure frequency related inclusion and exclu-
sion criteria and to document the retrospective baseline.
A cluster event was defined as the occurrence of more
than four generalized tonic-clonic seizures within 24 h
from onset of the first seizure within the cluster. If more
than one episode of >4 seizures was observed within one
24 h period, the whole seizure activity within this period
was counted as one cluster event. A status epilepticus was
defined as a state of continuous seizure activity lasting for
30 min or longer or repeated seizures with failure to
return to normal. Partial (focal) seizures were not consid-
ered for baseline evaluation.
Safety evaluation and treatment termination
During the study period, the owners had to keep a
patient diary for recording of occurrence and type of
seizures, adverse events, dates and times of dosing, and
potential changes in concomitant medication. At each
visit, a physical and neurological examination was per-
formed, and the patient diary entry was reviewed to-
gether with the patient owner. The seizure type and
frequency, as well as adverse events, were recorded. At
the screening visit and at the final visit, blood and urine
samples were taken for determination of safety labora-
tory values including hepatic and renal parameters, elec-
trolytes, total protein, albumin, and glucose, as well as a
complete blood count. Dogs that experienced four gen-
eralized tonic-clonic seizures, or any cluster seizure or
convulsive status epilepticus within the treatment period,
or were given prohibited medication were withdrawn
from the study for lack of efficacy. Likewise, dogs experi-
encing unacceptable tolerability related to the treatment,
as judged by the investigator or the patient owner, or
dogs suffering from concurrent disease not related to
the study treatment and judged to interfere with the
study conduct, were terminated. Patients could be with-
drawn from the study anytime upon withdrawal of the
owners’ consent or obvious non-compliance with the
study procedures. Withdrawn animals were included in
the final data analysis. Randomized animals withdrawn
from the study for any reason other than poor tolerabil-
ity could be replaced.
Study phase 2: 12 weeks open label follow up
Dogs that had completed the first phase of the study and
dogs that had prematurely terminated the first phase for
an exit criterion due to lack of efficacy were eligible to
enter in the second phase of the study as open-label fol-
low up. In this phase, all dogs were assigned to receive a
treatment of 30 mg/kg imepitoin twice daily, but the
owners remained blinded to the treatment during phase
1. The duration of this phase was 84 days, with the pos-
sibility of continued treatment on a compassionate basis.
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At the end of day 84 of the second phase of the study,
or earlier if any exit criterion was fulfilled, the investiga-
tor was to decide whether treatment could be continued
with imepitoin or whether the animal had to leave the
study to be treated with standard of care. All study pro-
cedures in phase 2 were similar as compared to the first
phase of the study, and visits were scheduled after
6 weeks and at the end of the treatment period, i.e. after
12 weeks, +/− 7 days. The combined treatment duration
in both successive phases of the study was 24 weeks.
Statistical evaluation of efficacy and safety
For efficacy evaluation, all treated animals with evaluable
retrospective baseline seizure frequency for which at
least one measurement of the primary efficacy variable
was available were included, representing the intent to
treat population (ITT). The change in monthly seizure
frequency (MSF) recorded during the treatment period
and in the retrospective baseline period was taken as the
primary efficacy endpoint. To calculate MSF, the retro-
spective baseline period (seizure history) and the study
period were each divided into six equal intervals (“bins”)
of 14 days each. All documented generalized tonic-
clonic seizures, clusters or status events were assigned
to the corresponding bin. Any cluster or status epilepti-
cus was counted as one seizure event. The seizure fre-
quency (seizures per 14 days) in a bin was defined as the
total number of seizures in the bin. Monthly seizure fre-
quencies were then calculated on the basis of one month
notionally equaling 28 days. All generalized tonic-clonic
seizures and clusters were considered; there were no
cases of convulsive status epilepticus during the treat-
ment period. The counting procedure was performed
under blinded conditions. The change in monthly seiz-
ure frequency was then obtained by subtracting the
arithmetic mean of all retrospective baseline bins from
the mean of all bins in the study period and was called
“monthly seizure frequency - change versus baseline”.
Negative values thus represent decreased seizure fre-
quencies, and positive values increased frequencies.
The difference between the change in MSF for the
high-dose group and the corresponding change for the
low-dose group, as well as the differences in mean MSF
prior to and at the end of the treatment period, was ana-
lyzed using Student’s two-sample t-test with pooled
standard deviation, using the two-sided model. To evalu-
ate the efficacy during the open label phase of the study,
MSF during the open label study was calculated the
same way. The difference between the MSF obtained in
phase 2 of the study and in phase 1 was evaluated sep-
arately for both treatment groups using the two-sample
t-test for two repeated measurements. The fraction of
animals which were free of generalized tonic-clonic sei-
zures was evaluated as a secondary endpoint separately
for both study phases and compared between the two
dose groups as well as between phase 1 and 2 using the
chi-square test for the equality of two independent pro-
portions following the two-sided model. In addition,
the total number of seizures occurring during the two
study periods were counted and classified as general-
ized tonic-clonic seizures, clusters, and partial or com-
plex partial seizures. The frequency of the different
seizure types was compared using a Normal-theory test
for the equality of two independent rates [23].
The safety of the study treatments was assessed on the
basis of adverse events (AEs) reported for all cases en-
rolled in the study which had been administered at least
one dose of study medication following classification
according to the VeDDRA list of preferred terms of the
system organ classes (European Medicines Agency
2004). The chi-square test for the equality of two pro-
portions was used to compare frequencies of adverse
events for individual categories. Laboratory data were
evaluated based on standard descriptive statistics and
were reviewed for conspicuous individual changes.
Results
Investigators in eight clinical referral centers specialized
in veterinary neurology in Germany and in one center in
Switzerland enrolled a total of 127 dogs in the study; 66
and 61 dogs were randomized to the high-dose and the
low-dose groups, respectively. All animals met all of the
inclusion criteria at screening: 55 and 54 dogs in the
high- and low-dose groups, respectively, with two to ten
tonic-clonic seizures during the 3-month baseline
period; 18 and 11 dogs in the high-dose and low-dose
groups, respectively, with one cluster of tonic-clonic
seizure within the seven days before randomisation; and
three and four dogs in the high-dose and low-dose
groups, respectively, with one convulsive status epilepti-
cus within seven days before randomization. Some of
these dogs fulfilled more than one of these criteria, and
none of the dogs met an exclusion criterion. Two dogs
of the high-dose and two dogs of the low-dose group
were removed from the ITT population. For one dog
assigned to the high-dose group, the owner withdrew
consent in the absence of any adverse event after the
first dose, and one dog in the high-dose group was not
included due to having been erroneously included as a
replacement of a dog euthanized after a cluster seizure.
One dog from the low-dose group was later diagnosed
to suffer from a brain tumor, and another dog from the
low-dose group had no available baseline seizure docu-
mentation, preventing evaluation of this dog for primary
efficacy, although the inclusion criteria were met. How-
ever, this dog was included in the evaluation of second-
ary efficacy parameters.
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Dogs from 60 different breeds were included with
mixed breed (18) having the greatest frequency, followed
by Golden Retriever (8), Labrador Retriever (7), German
Shepherd (7), Jack Russell Terrier (6), and various other
breeds, mostly with only one representative. While more
male than female dogs were included, the treatment
groups did not differ in their age and body weight (see
Table 1).
In all, 29 dogs (45 %) in the high-dose group and 30
dogs (50 %) in the low-dose group completed the full
12-week study treatment. The other dogs were either
withdrawn prematurely or ceased treatment early because
an exit criterion was fulfilled. In the high-dose group, the
occurrence of the 4th generalized tonic-clonic seizure or a
cluster seizure (10 and 17 cases, respectively) was the
most frequent exit criterion, while suspected adverse
reactions (4), consent withdrawal (3) and non-compliance
(1 case) were rare reasons. In the low-dose group, a simi-
lar distribution was seen, with 4th generalized tonic-clonic
seizure seen in 13 cases and cluster seizure in 11 cases
being most frequent. Suspected adverse reactions (1), con-
sent withdrawal (2) and non-compliance (3) were rare rea-
sons for premature discontinuation. All animals that
completed the treatment period or were withdrawn pre-
maturely for lack of efficacy were allowed to continue in
the open label phase of the trial. This procedure was
selected to enable the transition of the low-dose ani-
mals to high-dose treatment without having to break
the blind. Consequently, 53 out of 56 eligible dogs of
the former high-dose group continued with the open
label treatment, while 47 of 53 eligible dogs of the low-
dose group transitioned to the open label phase and
were started on 30 mg/kg BID. In the remaining dogs,
the owners withdrew consent for the 2nd phase of the
study.
Antiepileptic activity
The evaluation of the baseline seizure frequency of gener-
alized tonic-clonic seizures, cluster seizures or status
epilepticus events revealed that, in the high-dose group,
despite randomized inclusion, the mean seizure frequency
was found to be higher than in the low- dose group. This
difference was statistically significant (p = 0.030). In both
groups, the mean seizure frequency dropped during the
study period, but the drop was more pronounced in the
high-dose group, reaching a reduction of 1.7 ± 2.8 seizures
per month, while the drop in seizure frequency was only
0.8 ± 2.0 seizures per month in the low-dose group. This
mean difference was statistically significant (p = 0.044), in-
dicating that the high dose was superior to the low dose in
reducing seizure frequency (Table 2 and Fig. 1). In the
high-dose group, 37.5 % of animals (24 of 64) became seiz-
ure free, but also in the low-dose group 31.7 % (19 of 60)
became seizure free, the difference was not significant. In
addition, the total number of different seizure types which
occurred during the first study phase was counted and the
rate of seizures per dog was calculated. This included also
counting of partial and complex partial seizures, in
addition to generalized tonic-clonic and cluster seizures
(Table 3). Both groups differed significantly (p = 0.035) in
the rate of generalized tonic-clonic seizures, but not in
cluster seizures. The frequency of partial and complex
partial seizures was also significantly lower in the high-
dose group (p < 0.001). When all seizures were summed,
the total number of seizures was also significantly lower in
the high-dose group (p < 0.001).
In total 100 animals, 53 of the high-dose group and 47
of the low-dose group continued open label treatment in
phase 2 with BID 30 mg/kg imepitoin. There was no dif-
ference in MSF in the high-dose animals comparing
both study phases, indicating continued antiepileptic
activity. The reduction obtained during study initiation
was maintained with a mean MSF of 1.2 ± 1.3 in phase
2. In the animals of the former low-dose arm, the mean
MSF in phase 1 of the study was already low with 1.3 ± 1.8
seizures per month. The increase in dose to 30 mg/kg BID
resulted in a slight, but not significant, reduction in mean
MSF to 0.9 ± 1.4 seizures per month. However, the dose
increase resulted in an increased number of seizure free
dogs. Considering only the dogs which migrated to the
2nd study phase, 30.2 % (16 of 53 dogs) of the former
high-dose group and 29.8 % (14 of 47 dogs) of the
former low-dose group were seizure free at the start of
phase 2. During the 12 weeks open label treatment,
32.1 % (17 of 53) of the former high-dose animals were
seizure free, while in the former low- dose group the
increase in dose resulted in a rise in seizure free ani-
mals to 46.8 % (22 of 47 dogs). This increase in the
number of seizure free animals (8) during phase 2 for
the former low-dose animals, although just not statis-
tically significant (p = 0.055, one sided, or p =0.110,
two sided Chi-square test), is a noteworthy finding
(Table 2).





N = 60 (59a)
Total N = 124
(123a)
Sex (n) male 41 38 79
female 23 22 (21a) 45 (44a)
Age [years] Mean ± SD 3.9 ± 2.8 4.4 ± 2.7 4.1 ± 2.8
Range 0 - 13 0 - 13 0 - 13
Weight [Kg] Mean ± SD 26.3 ± 13.0 24.6 ± 13.9 25.4 ± 13.4
Range 3 - 65 2 - 74 2 - 74
aFor one animal no baseline data were available. It could therefore not be
included in the primary efficacy evaluation
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The total number of different seizure types which oc-
curred during the second study phase was counted, and
this included again also partial and complex partial sei-
zures (Table 3). The two groups did not differ signifi-
cantly in the number of generalized tonic-clonic
seizures, cluster seizures, and all seizures, as may be ex-
pected in that both groups were dosed with 30 mg/kg
BID in this study phase. However, if the study phases 1
and 2 were compared for the former low-dose group, it
became evident that the rates of generalized tonic-clonic
seizures, partial or complex partial seizures, and of all
seizures were significantly reduced, while the rate of
cluster seizures was not different (Table 3). In contrast,
in the former high-dose group, which was continued on
30 mg/kg BID, there was no significant change in seizure
rate with the exception of partial seizures, which were
further reduced (p < 0.001) (Table 3). These data indi-
cate, that the antiepileptic activity reached in phase 1 of
the study was maintained in phase 2.
Safety
The safety evaluation included all 127 cases that had
obtained at least one dose of active drug. At least one
adverse event (AE) was observed for 86 % of the high-
dose animals, and for 82 % of the low-dose group ani-
mals during study phase 1. The total number of reports
was 213 in the high-dose group and 168 in the low-dose
group. The number of reports of AEs in the high-dose
group was greater than in the low-dose group, but the
numbers of dogs affected were not substantially different
between the two groups (p = 0.497 for any event). If only
the dogs with AEs which were judged to be likely treat-
ment related, i.e. which were classified as adverse reac-
tions (ARs) were concerned, the high-dose animals were
significantly more frequently affected (p = 0.041). The in-
cidence of dogs affected by AEs and ARs in each body
system was generally about the same in the two groups,
with the following three exceptions. There were signifi-
cantly more dogs with CNS-related AEs in the high-
dose group (p = 0.018), and more of these were rated as
Table 2 Monthly seizure frequency (MSF) and proportion of seizure free animals during phase 1 and 2
High-dose N = 64 Low-Dose N = 60 (59a) Significanceb, high-dose
vs. low-dose group
MSF Baseline Mean ± SD 2.9 ± 2.7 2.0 ± 1.7 p = 0.030
95 CI of mean 2.2 - 3.6 1.6 – 2.5
MSF During phase 1 Mean ± SD 1.2 ± 1.7 1.3 ± 1.8 p = 0.751
95 CI of mean 0.7 - 1.6 0.8 - 1.7
MSF Change to baseline Mean ± SD −1.7 ± 2.8 −0.8 ± 2.0 p = 0.044
95 CI of mean −2.4 - -1.1 −1.3 - -0.3
Seizure free animals during phase 1 [n] 24 of 64 19 of 60 p = 0.495
Transition to phase 2 N = 53 of 64 N = 47 of 60
MSF During phase 2 Mean ± SD 1.2 ± 1.3 0.9 ± 1.4 p = 0.269
95 CI of mean 0.8 - 1.5 p = 0.688c 0.5 - 1.4 p =0.369c
Seizure free animals at start of phase 2 [n] 16 of 53 14 of 47 p = 0.965
Seizure free animals during phase 2 [n] 17 of 53 p = 0.540c 22 of 47 p = 0.110c p = 0.132
aFor one animal no baseline data were available. It could therefore not be included in the primary efficacy evaluation
bThe p-value for the difference in mean MSF and change in MSF was based on the two-sided two-sample t-test; the p-value difference in the proportion of seizure
free animals was based on the two-sided chi-square test for two samples
cComparison of results from phase 1 and phase 2 of the study
Fig. 1 Reduction in monthly seizure frequency (MSF) during study
phase 1. Displayed are mean ± SD of the difference in MSF prior to
start of treatment (retrospective baseline) and during treatment with
1 mg/kg BID (Low dose) or 30 mg/kg BID (high dose). The MSF was
significantly more reduced in the high dose group (two-sided
two-sample t-test)
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ARs (p = 0.031). These ARs were predominantly ataxia,
disorientation (and disturbance of equilibrium or co-
ordination), hyperactivity, and restlessness. There was a
trend for a higher rate of ARs for the musculoskeletal
system in the high-dose compared to the low-dose
group, but the difference did not reach level of signifi-
cance (p = 0.057, Table 4). These were largely related to
motor activity, and thus overlap with hyperactivity and
restlessness. Most AEs were mild or moderate. Gastro-
intestinal events were relatively frequent in both groups,
but no relationship to the dose was seen, so these may
be assumed not to have been caused by the study treat-
ment. In most cases, the AEs were transient and
observed primarily during only the first weeks of treat-
ment; this applied especially to the AEs observed most
often in the high-dose group, e.g., ataxia and disorienta-
tion, as well as hyperactivity (details not shown).
In phase 2 of the study, the total number of reports
of adverse events was 208 (95 in dogs from the former
high-dose group and 113 in dogs from the former low-
dose group. The frequency of reports and a likely
relationship to the study treatment as rated by the investi-
gator were somewhat higher in dogs from the former low-
dose group, but no significant difference could be seen
between both groups. The distribution of AEs by organ
systems was similar to the findings in phase 1, including a
relatively high frequency of CNS-related events and the
transient nature of the CNS-related events (data not
shown).
At the time of enrolment of the dogs in the study,
there were no significant differences between the treat-
ment groups with respect to the blood chemistry indica-
tors including markers of hepatic and renal function,
and in both treatment groups, similar frequencies of ani-
mals with individual values outside the reference values
of the analytical laboratory were found during visit one.
At the end of study phase 1, blood chemistry indicators
were in general unchanged for both groups; some values
(hepatic values: alanine aminotransferase, alkaline phos-
phatase, glutamate dehydrogenase) even improved dur-
ing the study in both groups (data not shown). There
was a slight tendency that creatinine values increased in
Table 3 Number of different seizure types and average seizure rate per animal
High dose (30 mg/kg) Low dose (1 mg/kg) High
dose in Phase 2
Significancea, high dose
vs. low dose group
Seizure type Total number (rate) Total number (rate)
Phase 1: Primary Efficacy
Evaluation
Number of animals in phase 1 N = 64 N = 60
Generalized tonic-clonic seizures 73 (1.14) 95 (1.58) p = 0.035
Cluster seizures 17 (0.27) 9 (0.15) p = 0.156
Partial or complex partial seizures 30 (0.47) 75 (1.25) p < 0.001
Total during part 1 120 (1.88) 179 (2.98) p < 0.001
Phase 2: Extended use at
high dose
Number of animals in phase 2 N = 53 N = 47
Generalized tonic-clonic 60 (1.13) p = 0.966b 45 (0.96) p = 0.004b p = 0.393
Cluster seizures, convulsive status 21 (0.40) p = 0.226b 9 (0.19) p = 0.609b p = 0.057
Partial or complex partial seizures 5 (0.09) p < 0.001b 19 (0.40) p < 0.001b p = 0.002
Total during phase 2 86 (1.62) p = 0.303b vs. phase 1 73 (1.55) p = 0.001b p = 0.783
aBased on the Normal-theory test for the difference in rates between two independent samples [23]
bComparison of results from phase 1 and phase 2 of the study
Table 4 Summary of most frequent adverse events by organ system, number of dogs affected
Category of adverse events High dose, N = 66 Number of dogs
(dogs with likely treatment relation)
Low dose, N = 61 Number of dogs
(dogs with likely treatment relation)
Significancea, high vs. low-dose group
(dogs with likely treatment relation)
Any 57 (39) 50 (25) p = 0.497 (p = 0.041)
Central nervous systemb 48 (33a) 32 (19a) p = 0.018 (p = 0.031)
Gastro-intestinal system 32 (8) 25 (2) p = 0.396 (p = 0.065)
Musculoskeletal system 12 (10) 8 (3) p = 0.443 (p = 0.057)
Respiratory system 7 (4) 8 (4) p = 0.662 (p = 0.908)
General 5 (2) 5 (2) p = 0.897 (p = 0.936)
Urogenital tract 4 (1) 5 (1) p = 0.639 (p = 0.956)
Other systems 14 (10) 15 (3) p = 0.650 (p = 0.057)
aBased on the two-sided chi-square test for the equality of proportions from two independent samples
bMainly seen during first weeks of treatment
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the high-dose group from 84.9 ± 21.5 μmol/l to 99.5 ±
26.4 μmol/l, while the change was minimal in the low-
dose group from 82.2 ± 21.0 to 84.0 ± 19.9 μmol/l at the
end of study phase 1. During study phase 2, the creatin-
ine value did not change further in the high-dose group
(96.4 ± 31.0 μmol/l), while in the former low-dose group
the creatinine levels slightly increased to 91.9 ±
25.8 μmol/l. However, all measurements remained
within the normal range. Hematological values were
stable in both groups during both study periods (data
not shown).
Discussion
The purpose of the current study was to demonstrate an-
tiepileptic activity and safety of imepitoin in dogs with
generalized tonic-clonic seizures suffering from idiopathic
epilepsy. The diagnosis was primarily based on seizure his-
tory in combination with a normal clinical and neuro-
logical examination as well as normal laboratory data to
exclude extracerebral causes of seizures or progressive
intracranial disease such as neoplasia or inflammation.
This procedure does not preclude the inclusion of patients
with other than idiopathic epilepsy, such as patients with
cryptogenic or symptomatic epilepsy. The prevalence of
clinically significant MRI abnormalities in dogs below the
age of 6 years with seizures without interictal neurological
deficits was previously found to be one out of 46 dogs
[24], indicating that the vast majority of the dogs included
in this study, which were aged 3.9 ± 2.8 and 4.4 ± 2.7 years,
had indeed idiopathic epilepsy. Only 26 of 127 dogs were
aged above 6 years, with 10 each being 7 and 8 years old
at inclusion. However, it cannot be excluded that individ-
ual dogs with undetermined causes of epilepsy had been
also included. Indeed, one dog was excluded from efficacy
evaluation prior to unblinding due to other causes of sei-
zures determined by MR imaging.
The optimal study design to demonstrate a clinical
effect in a controlled field study is to conduct a random-
ized double blind placebo controlled study with a suffi-
ciently long prospective baseline to establish an exact
measure of baseline seizure activity. However, a seizure
disease presents with massive behavioral manifestations,
and if patient owners seek help for treatment of this dis-
ease, a placebo controlled study and a prospective base-
line was at the time of the study conduct ethically
questionable. Add-on trials to established antiepileptic
drugs in patients with drug resistant epilepsy has been
the primary approach for many years in human medi-
cine. Because co-administered drugs are subject to drug
interactions, add-on trials of antiepileptic drugs do not
necessarily address the utility of a new drug as mono-
therapy or its use in patients with newly diagnosed epi-
lepsy [25]. A low-dose active comparator design was
therefore developed to enable demonstration of clinical
efficacy of a new drug using a superiority design [25].
We have selected and adapted this design principle and
have compared a low dose of 1 mg/kg BID of imepitoin
with the high dose of 30 mg/kg BID, involving a double-
blind placebo-controlled parallel group study design
with retrospective baseline. While the retrospective
baseline did introduce possibility for inaccurate record-
ing of seizure activity, this was minimized by focusing
on generalized tonic-clonic seizures, clusters, and status
epilepticus events, which, due to their severity, can be
well memorized and counted. The selection of the low
dose was based on a previous pilot study and on preclin-
ical data in seizure models. In an open label pilot study,
first antiepileptic effects were seen at a starting dose of
5 mg/kg BID [19, 20]. Experimental data indicated that
doses as low as 1 mg/kg of imepitoin were capable of
elevating the seizure threshold in the amygdala kindling
model of epilepsy in rats [17], and with a dose of
5 mg/kg administered once daily for up to 40 days, the
threshold for induction of seizures was significantly el-
evated in dogs [19]. Based on these data, the dose of
1 mg/kg, administered BID, was selected as the poten-
tial lowest dose with antiepileptic activity. The high
dose was selected from the highest dose tested in the
pilot study, which was also found to be safe [19, 20].
The study design developed consisting of the de-
scribed two treatment phases enabled the evaluation
of antiepileptic activity over a total treatment period
of 6 months in dogs, which were continued at the high
dose, and in fact, the antiepileptic activity obtained
during the first 12 weeks was maintained during the
2nd study phase. Moreover, 17 dogs continued treat-
ment under compassionate use and were followed up
for up to 2 years, maintaining antiepileptic activity
(data not shown).
In this study, we focused on previously untreated dogs
with epilepsy. The aim was to select a homogenous
group of newly diagnosed patients, but the inclusion cri-
teria allowed for both patients with a history of
untreated generalized tonic-clonic seizures and also pa-
tients with a recent history of a single cluster seizure
event or a recent status event. While most patients had
a history of generalized tonic-clonic seizures, 29 dogs
had one or more clusters of tonic-clonic seizures, and
nine dogs had one convulsive status epilepticus within
the seven days before randomization. Those seizure
events were either the sole event or probably the reason
why the owner sought medical treatment. Patients which
had experienced cluster seizures are known to be signifi-
cantly less likely to achieve remission upon any antiepilep-
tic treatment [26]. Our inclusion criteria allowed therefore
the inclusion of potentially drug resistant dogs. By chance,
18 animals with clusters were included in the high-dose
group, while only nine animals with clusters were included
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in the low-dose group during randomization. In addition,
MSF at baseline was found to be significantly higher in the
high-dose group, as compared to the low-dose group
(Table 2). However, since the individual difference in MSF
during baseline and during study phase 1 was used to
evaluate clinical efficacy, this baseline difference had little
influence on the primary efficacy outcome. MSF in ani-
mals treated with the high dose was significantly more
reduced than in the low-dose group, indicating that a high
dose of imepitoin is superior to a low dose in reducing the
monthly frequency of generalized tonic-clonic seizures.
The MSF was also reduced in the low-dose arm, and
even 19 of 60 dogs evaluated were free of generalized
seizures during study phase 1. While one may conclude
that the dose of 1 mg/kg given BID may be indeed ef-
fective in at least a subset of dogs, other factors need to
be considered. The seizure frequency in epileptic dis-
eases fluctuates over time, with times of higher fre-
quency, and times with fewer seizures, as has been
shown in childhood epilepsy [27]. If owners of previously
untreated patients are seeking treatment, one may rea-
sonably assume that this decision was guided by a recent
experience of seizure events, potentially marking a
period of increased seizure activity. As soon as treat-
ment, including placebo treatment, is initiated, the
period of increased activity may be followed spontan-
eously by a period with reduced seizure activity, without
causal relation to the treatment [27]. This phenomenon is
called regression to the mean [28, 29]. The Hawthorne-
effect, i.e. the change in behavior due to the fact that a pa-
tient (or the patient owner) is participating in a clinical
study, and the placebo effect, which is induced by the fact
that a patient (or in case of pets the pet owner) may
expect a pharmacological effect from a new treatment,
may also contribute to the reduction in seizure frequency
in the low-dose or placebo group [30]. Burneo et al. [29]
conducted a meta-analysis of placebo controlled trials in
epilepsy in man. They found, that due to all three factors,
9.3-16.6 % of patients in the placebo arm had a >50 %
reduction in seizure frequency. This effect represented
20-50 % of the activity observed for the active agents. It
is therefore likely that at least a proportion of the re-
duction in MSF may not be linked to pharmacological
activity of the 1 mg/kg BID dose. In a seizure threshold
model in dogs, significant effects were seen for an oral
dose of 5 mg/kg administered once daily if the seizure
event was induced at the time of peak plasma level, in-
dicating that low doses can have an antiepileptic effect
[19]. While lower doses than 5 mg/kg have not been
tested in this model, the small threshold effect observed
at 5 mg/kg makes it unlikely that a dose of 1 mg/kg can
have sufficient antiepileptic activity to solely explain
the MSF reduction in the low-dose group. A meta-
analysis of three placebo-controlled clinical trials in
epileptic dogs could verify a placebo response in dogs
with epilepsy [31], and a clear placebo response was
also seen in a study testing levetiracetam using a cross
over design [32].
The percentage of patients which were free of general-
ized tonic-clonic seizures was evaluated as a secondary
endpoint. In the high-dose group, 37.5 % and in the low-
dose group 31.7 % of all animals were seizure free during
the first study phase. The lack of a significant difference
between the two treatment groups is likely due to the
difference in baseline seizure activity, which was higher
in the high-dose group. In the animals from the low-
dose group which were treated with the high dose in the
2nd phase of the study, the number of animals which
were free of generalized tonic-clonic seizures reached
46.8 % (22 of 47 dogs), up from 29.8 % at start of
phase 2, indicating increased activity of the high dose
over the low dose, while in the high-dose animals
which were maintained on high dose the fraction of
seizure free animals was 32.1 %, indicating stable anti-
epileptic activity. In a recent review of 344 dogs
undergoing antiepileptic treatment of any kind in a
referral clinic, only 14 % became seizure free [26],
indicating that imepitoin is very efficacious in respon-
sive patients. While the number of seizure-free dogs
increased in the former low-dose group during study
phase 2, MSF was only slightly further lowered in this
group (Table 2). This may be related to the fact that
about one third of animals has been reported to
remain treatment resistant with any treatment [11],
and thus this fraction of animals did not improve with
imepitoin.
Generalized tonic-clonic seizures (as well as cluster
seizures or status epilepticus events) are conditions
which are disruptive for the patient owner as well as for
the patient. We focused on these seizure types to define
the efficacy of imepitoin. These seizures could be also
safely classified for the retrospective seizure history [33].
During the treatment periods, the owners were required
to keep a daily diary and were educated to identify and
record also partial and complex partial seizure activity.
The treatment with imepitoin at 30 mg/kg BID resulted
in a significant reduction in all seizure types except for
cluster seizures compared to the low-dose treatment in
phase 1, and upon continuation in phase 2, all seizure
types except for cluster seizures were significantly
reduced when the dose was increased from 1 mg to
30 mg/kg BID in phase 2. Partial and complex partial
seizures were most strongly reduced in the high-dose
group as compared to the low-dose group during study
phase 1, and when the low-dose animals were dosed
with the high dose in the 2nd study phase, the number of
partial seizures was also significantly reduced, indicat-
ing that imepitoin may have a potent effect against
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these seizure types (Table 3). Imepitoin is a low affinity
partial agonist at the benzodiazepine receptor [17].
Benzodiazepines are long known to be active against
diverse seizure types including partial seizures, complex
partial seizures, absence seizures, and myoclonic sei-
zures, in addition to generalized tonic- clonic seizures
[34, 35]. The interesting activity of imepitoin against
partial and complex partial seizures may therefore be
related to its mode of action.
Antiepileptic treatment requires chronic medication.
While benzodiazepines are generally known to be potent
antiepileptics, their clinical use in man is limited by the
development of tolerance to the antiepileptic activity
[34]. In various experimental models imepitoin has not
been shown to be susceptible to tolerance development
[17, 19]. We now demonstrate that, in a clinical field set-
ting, no tolerance developed to the antiepileptic activity
of imepitoin during continuous treatment for up to
6 months under field conditions. Imepitoin may there-
fore be used for long-term treatment without risk of los-
ing antiepileptic activity. The suitability for long-term
use is also supported by the safety profile of imepitoin as
found in this study. The most frequent organ systems
with an observed adverse event were the CNS, gastro-
intestinal system, and musculoskeletal system; however,
only few findings in the gastrointestinal system were
judged to be treatment related by the investigator. The
CNS and musculoskeletal system related ARs reported
in this study, i.e. ataxia, disorientation, hyperactivity, and
restlessness, are similar to the ARs reported in a previ-
ously reported clinical study [21]. It is however interest-
ing to note, that these findings were reported by the
investigators to be transient. The possible treatment re-
lation of these CNS related findings is supported by the
fact, that in the 2nd phase of the study, the frequency of
these findings increased in the dogs which had been pre-
viously dosed with the low dose. Again, the investigators
reported that these findings were predominantly in the
first weeks of treatment with the high dose. The transi-
ent nature of the CNS related ARs has been also
reported in the pilot study of imepitoin [19, 20]. The
safety profile of imepitoin differs markedly from pheno-
barbital, which has been found to induce significantly
more CNS-related symptoms including somnolence/
sedation and neurological disorders, but also signifi-
cantly more other ARs, including increased appetite,
polydipsia, polyuria, renal/urinary disorders and diar-
rhea [21]. Only hyperactivity had been found to be sig-
nificantly more frequent for the imepitoin group [21].
Our study results now indicate that these findings are
transient for imepitoin.
Both, clinical biochemistry and hematology investiga-
tions did not reveal any clinically relevant ARs. Liver en-
zymes were not increased and, in phase 1, were even
reduced – again in contrast to the findings observed for
phenobarbital [21]. A marginal increase in mean creatin-
ine was observed in our study, and the treatment rela-
tion could be confirmed by the fact that the same
increase was seen in study phase 2 in dogs of the former
low-dose group. In dogs which were maintained on the
high dose, no further increase in creatinine was seen. No
other changes in kidney related safety parameters were
seen. Because only a marked damage of functioning
nephrons can result in increased creatinine levels in
serum [36], and because such damage was not seen even
following dosing of 150 mg/kg imepitoin for 6 months
[21], the increased serum creatinine level may be a result
of increased muscular turnover and not an indicator of
kidney dysfunction. An alternative explanation to the
slight but discrete increase in creatinine may be related
to the analytical method used. Indeed, the standard
method is highly susceptible to interference by many
factors, including drugs and metabolites [37].
Conclusion
Based on the results of this clinical randomized con-
trolled field study the administration of imepitoin twice
daily at a dose of 30 mg/kg results in significant and per-
sistent antiepileptic effects in patients with newly diag-
nosed epilepsy suffering from generalized tonic-clonic
seizures, as observed over a study period of up to
6 months. The safety profile of imepitoin was good, and
mostly CNS related ARs were transient and predomin-
antly observed in the first weeks of treatment. Both, the
antiepileptic activity and the safety profile lacking hep-
atotoxicity or other organ toxicity make the drug suit-
able for long-term clinical use at the recommended
therapeutic dose.
Abbreviations
AE: Adverse event (all); AED: Antiepileptic drug; AR: Adverse reaction (with
possible or likely treatment relation); BID: Twice daily; CNS: Central nervous
system; GCP: Good clinical practice; ITT: Intent to treat population;
MSF: Monthly seizure frequency.
Competing interests
The study was funded by elbion AG, Radebeul, Germany, the employer of Dr.
Chris Rundfeldt at the time of study conduct. Prof. Andrea Tipold has been
principal investigator of the described clinical study. Dr. Chris Rundfeldt and
Prof. Wolfgang Löscher are scientific advisors to Boehringer Ingelheim
Vetmedica GmbH, Germany, the marketing authorization holder of Pexion®,
containing Imepitoin as active principle.
Authors’ contribution
CR contributed to the study design, supervised the study conduct,
contributed to the discussion of the study results, and edited the
manuscript. AT served as principal investigator and contributed to the
design and conduct of the study. WL contributed to the study design and to
the discussion of the results. All authors approved the manuscript.
Acknowledgement
We thank Dr. med. vet. B. Krebs-Breuer, Mühlheim, Dr. med. vet. F. König,
Wiesbaden, Dr. med. vet. A. Stolle-Malorny, Berlin, Dr. med. vet. M. Kornberg,
Trier, Dr. med. vet. S. Gaida, Wiesloch, Dr. med. vet. S. Medl, Babenhausen, Dr.
Rundfeldt et al. BMC Veterinary Research  (2015) 11:228 Page 10 of 11
med. vet. K. Jurina, Haar, and Prof. Dr. med. vet. A. Jaggy, Bern for participation
in the study as clinical investigators. We thank Dr. M. Brosz, and Dr. U. Schmidt,
StatConsult, Magdeburg, Germany, and Prof. Thomas Keefe, Colorado State
University, Fort Collins, USA, for statistical analysis of the data.
Author details
1Drug-Consulting Network, 01445 Coswig, Germany. 2Department of Small
Animal Medicine and Surgery, University of Veterinary Medicine, Hannover,
Germany. 3Center for Systems Neuroscience, 30559 Hannover, Germany.
4Department of Pharmacology, Toxicology and Pharmacy, University of
Veterinary Medicine Hannover, 30559 Hannover, Germany.
Received: 27 April 2015 Accepted: 26 August 2015
References
1. Mariani CL. Terminology and classification of seizures and epilepsy in
veterinary patients. Top Companion Anim Med. 2013;28:34–41.
2. Podell M, Fenner WR, Powers JD. Seizure classification in dogs from a
nonreferral-based population. J Am Vet Med Assoc. 1995;206:1721–8.
3. Loscher W, Schwartz-Porsche D, Frey HH, Schmidt D. Evaluation of epileptic
dogs as an animal model of human epilepsy. Arzneimittelforschung.
1985;35:82–7.
4. Steinmetz S, Tipold A, Loscher W. Epilepsy after head injury in dogs: a
natural model of posttraumatic epilepsy. Epilepsia. 2013;54:580–8.
5. Patterson EN. Epileptogenesis and companion animals. Top Companion
Anim Med. 2013;28:42–5.
6. Kearsley-Fleet L, O’Neill DG, Volk HA, Church DB, Brodbelt DC. Prevalence
and risk factors for canine epilepsy of unknown origin in the UK. Vet Rec.
2013;172:338.
7. Oberbauer AM, Grossman DI, Irion DN, Schaffer AL, Eggleston ML, Famula
TR. The genetics of epilepsy in the Belgian tervuren and sheepdog. J Hered.
2003;94:57–63.
8. Thomas WB, Dewey CW. Seizures and narcolepsy. In A practical guide to
canine and feline neurology. Dewey CW, editor. Hoboken, NJ, USA: John
Wiley & Sons;
2008; p. 237–59.
9. Charalambous M, Brodbelt D, Volk HA. Treatment in canine epilepsy–a
systematic review. BMC Vet Res. 2014;10:257. doi:10.1186/s12917-014-0257-
9.:257-0257.
10. Wright HM, Chen AV, Martinez SE, Davies NM. Pharmacokinetics of oral
rufinamide in dogs. J Vet Pharmacol Ther. 2012;35:529–33.
11. Potschka H, Fischer A, von Ruden EL, Hulsmeyer V, Baumgartner W. Canine
epilepsy as a translational model? Epilepsia. 2013;54:571–9.
12. Trepanier LA, Van SA, Schwark WS, Carrillo J. Therapeutic serum drug
concentrations in epileptic dogs treated with potassium bromide alone or
in combination with other anticonvulsants: 122 cases (1992–1996). J Am Vet
Med Assoc. 1998;213:1449–53.
13. Berendt M, Gredal H, Ersboll AK, Alving J. Premature death, risk factors, and
life patterns in dogs with epilepsy. J Vet Intern Med. 2007;21:754–9.
14. Speciale J, Dayrell-Hart B, Steinberg SA. Clinical evaluation of gamma-vinyl-
gamma-aminobutyric acid for control of epilepsy in dogs. J Am Vet Med
Assoc. 1991;198:995–1000.
15. Schwartz M, Munana KR, Olby NJ. Possible drug-induced hepatopathy in a
dog receiving zonisamide monotherapy for treatment of cryptogenic
epilepsy. J Vet Med Sci. 2011;73:1505–8.
16. Ziolkowski H, Jaroszewski JJ, Ziolkowska N, Jasiecka A. Characteristics of
selected second-generation antiepileptic drugs used in dogs. Pol J Vet Sci.
2012;15:571–82.
17. Rundfeldt C, Loscher W. The pharmacology of imepitoin: the first partial
benzodiazepine receptor agonist developed for the treatment of epilepsy.
CNS Drugs. 2014;28:29–43.
18. Rundfeldt C, Gasparic A, Wlaz P. Imepitoin as novel treatment option for
canine idiopathic epilepsy: pharmacokinetics, distribution, and metabolism
in dogs. J Vet Pharmacol Ther. 2014;37:421–34.
19. Loscher W, Potschka H, Rieck S, Tipold A, Rundfeldt C. Anticonvulsant
efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138
in a dog seizure model and in epileptic dogs with spontaneously recurrent
seizures. Epilepsia. 2004;45:1228–39.
20. Rieck S, Rundfeldt C, Tipold A. Anticonvulsant activity and tolerance of
ELB138 in dogs with epilepsy: a clinical pilot study. Vet J. 2006;172:86–95.
21. Tipold A, Keefe TJ, Loscher W, Rundfeldt C, de VF. Clinical efficacy and safety
of imepitoin in comparison with phenobarbital for the control of idiopathic
epilepsy in dogs. J Vet Pharmacol Ther. 2014;10.
22. Vandevelde M, Jaggy A, Lang J, Falkhauser R. Veterinary neurology. A guide
for students and practitioners. (Veterinärmeizinische Neurologie. ein
Leitfanden für Studium und Praxis). Parrey Buchverlag, Berlin; 2001.
23. Rothman KJ. Modern epidemiology. Boston: Little, Brown and Company.
1986. p. 170–1.
24. Smith PM, Talbot CE, Jeffery ND. Findings on low-field cranial MR images in
epileptic dogs that lack interictal neurological deficits. Vet J. 2008;176:320–5.
25. Sachdeo R. Monotherapy clinical trial design. Neurology. 2007;69:S23–7.
26. Packer RM, Shihab NK, Torres BB, Volk HA. Clinical risk factors associated
with anti-epileptic drug responsiveness in canine epilepsy. PLoS ONE. 2014.
27. Pujar S, Calvert S, Cortina-Borja M, Chin RF, Smith RA, Cross JH, et al.
Statistical process control (SPC)–a simple objective method for monitoring
seizure frequency and evaluating effectiveness of drug interventions in
refractory childhood epilepsy. Epilepsy Res. 2010;91:205–13.
28. Morton V, Torgerson DJ. Regression to the mean: treatment effect without
the intervention. J Eval Clin Pract. 2005;11:59–65.
29. Burneo JG, Montori VM, Faught E. Magnitude of the placebo effect in
randomized trials of antiepileptic agents. Epilepsy Behav. 2002;3:532–4.
30. Dumitriu A, Popescu BO. Placebo effects in neurological diseases. J Med
Life. 2010;3:114–21.
31. Munana KR, Zhang D, Patterson EE. Placebo effect in canine epilepsy trials. J
Vet Intern Med. 2010;24:166–70.
32. Munana KR, Thomas WB, Inzana KD, Nettifee-Osborne JA, McLucas KJ, Olby
NJ, et al. Evaluation of levetiracetam as adjunctive treatment for refractory
canine epilepsy: a randomized, placebo-controlled, crossover trial. J Vet
Intern Med. 2012;26:341–8.
33. Packer RM, Berendt M, Bhatti S, Charalambous M, Cizinauskas S, De RL, et al.
Inter-observer agreement of canine and feline paroxysmal event semiology
and classification by veterinary neurology specialists and non-specialists.
BMC Vet Res. 2015;11:39.
34. Robertson MM. Current status of the 1,4- and 1,5-benzodiazepines in the
treatment of epilepsy: the place of clobazam. Epilepsia. 1986;27 Suppl
1:S27–41. S27-S41.
35. Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its
pharmacological properties and therapeutic efficacy in epilepsy. Drugs.
1976;12:321–61.
36. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function
equations for patients with chronic kidney disease and normal serum
creatinine levels. J Am Soc Nephrol. 2002;13:2140–4.
37. Peake M, Whiting M. Measurement of serum creatinine–current status and
future goals. Clin Biochem Rev. 2006;27:173–84.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rundfeldt et al. BMC Veterinary Research  (2015) 11:228 Page 11 of 11
